This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Celgene Corporation (CELG): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation (
CELG) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.5%. By the end of trading, Celgene Corporation fell $3.31 (-2.1%) to $152.62 on average volume. Throughout the day, 2,718,491 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,519,200 shares. The stock ranged in price between $150.46-$155.95 after having opened the day at $155.50 as compared to the previous trading day's close of $155.93. Other companies within the Health Care sector that declined today were:
Mast Therapeutics (
MSTX), down 33.1%,
Delcath Systems (
DCTH), down 11.9%,
Zalicus (
ZLCS), down 11.7% and
DARA Biosciences (
DARA), down 10.8%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $60.2 billion and is part of the drugs industry. Shares are up 86.6% year to date as of the close of trading on Wednesday. Currently there are 20 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates
Celgene Corporation as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.